Randomized phase II study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed primary glioblastoma multiforme.

被引:0
|
作者
Hofland, K. F.
Hansen, S.
Sorensen, M.
Schultz, H. P.
Muhic, A.
Engelholm, S.
Ask, A.
Kristiansen, C.
Thomsen, C.
Poulsen, H. Skovgaard
Lassen, U. N.
机构
[1] Rigshosp, Dept Oncol, Finsenctr 5073, DK-2100 Copenhagen, Denmark
[2] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
[3] NBG, Onkol Afdeling D, Aarhus, Denmark
[4] Roskilde Hosp, Dept Oncol, Copenhagen, Denmark
[5] Dept Oncol Malmoe Lund, Lund, Sweden
[6] Rigshosp, Ctr Diagnost, Dept Radiol, DK-2100 Copenhagen, Denmark
关键词
D O I
10.1200/jco.2011.29.15_suppl.2052
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2052
引用
收藏
页数:1
相关论文
共 50 条
  • [1] RANDOMIZED PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB AND IRINOTECAN VERSUS BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY IN NEWLY DIAGNOSED PRIMARY GLIOBLASTOMA MULTIFORME
    Hofland, Kenneth F.
    Hansen, Steinbjorn
    Sorensen, Morten
    Schultz, Henrik
    Muhic, Aida
    Engelholm, Silke
    Ask, Anders
    Kristiansen, Charlotte
    Thomsen, Carsten
    Poulsen, Hans S.
    Lassen, Ulrik N.
    NEURO-ONCOLOGY, 2011, 13 : 51 - 52
  • [2] Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study
    Hofland, Kenneth F.
    Hansen, Steinbjorn
    Sorensen, Morten
    Engelholm, Silke
    Schultz, Henrik P.
    Muhic, Aida
    Grunnet, Kirsten
    Ask, Anders
    Costa, Junia C.
    Kristiansen, Charlotte
    Thomsen, Carsten
    Poulsen, Hans Skovgaard
    Lassen, Ulrik
    ACTA ONCOLOGICA, 2014, 53 (07) : 939 - 944
  • [3] BEVACIZUMAB IN COMBINATION WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Vredenburgh, James
    Desjardins, Annick
    Reardon, David
    Rich, Jeremy
    Kirkpatrick, John
    Gururangan, Sridharan
    Bailey, Leighann
    Friedman, Allan
    Bigner, Darell
    Friedman, Henry
    NEURO-ONCOLOGY, 2008, 10 (05) : 836 - 837
  • [4] Radiotherapy, temozolomide, and bevacizumab followed by irinotecan, temozolomide and bevacizumab in newly diagnosed glioblastoma multiforme: Preliminary results front an ongoing phase II trial
    Kirkpatrick, J. P.
    Desjardins, A.
    Reardon, D. A.
    Vredenburgh, J. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S209 - S209
  • [5] FIRST-LINE THERAPY WITH BEVACIZUMAB AND IRINOTECAN VERSUS BEVACIZUMAB AND TEMOZOLOMIDE AND DELAYED CONCOMITANT RADIOTHERAPY IN NEWLY DIAGNOSED PRIMARY GLIOBLASTOMA MULTIFORME: EARLY RESULTS FROM A RANDOMIZED PHASE II STUDY
    Hofland, Kenneth F.
    Poulsen, Hans Skovgaard
    Sorensen, Morten P.
    Ask, Anders
    Bertelsen, Anne K.
    Spahn-Horn, Silke
    Hansen, Steinbjorn
    Schulz, Henrik P.
    Lassen, Ulrik
    NEURO-ONCOLOGY, 2009, 11 (05) : 620 - 620
  • [6] Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme
    Vredenburgh, James J.
    Desjardins, Annick
    Peters, Katherine B.
    Reardon, David A.
    Herndon, James Emmett
    Coan, April D.
    Kirkpatrick, John
    Bailey, Leighann
    Threatt, Stevie
    Sampson, John Howard
    Friedman, Allan H.
    Friedman, Henry S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Radiotherapy, Temozolomide and Bevacizumab followed by Irinotecan, Temozolomide and Bevacizumab Appears Well-tolerated and Efficacious in Newly Diagnosed Glioblastoma Multiforme: Results from a Phase II Trial
    Kirkpatrick, J. P.
    Desjardins, A.
    Reardon, D. A.
    Friedman, A. H.
    Friedman, H. S.
    Vredenburgh, J. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S102 - S103
  • [8] The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma
    Vredenburgh, James J.
    Desjardins, Annick
    Reardon, David A.
    Peters, Katherine B.
    Herndon, James E., II
    Marcello, Jennifer
    Kirkpatrick, John P.
    Sampson, John H.
    Bailey, Leighann
    Threatt, Stevie
    Friedman, Allan H.
    Bigner, Darell D.
    Friedman, Henry S.
    CLINICAL CANCER RESEARCH, 2011, 17 (12) : 4119 - 4124
  • [9] PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Ranjan, Tulika
    Desjardins, Annick
    Peters, Katherine B.
    Alderson, Lloyd
    Kirkpatrick, John
    Herndon, James, II
    Bailey, Leighann
    Sampson, John
    Friedman, Allan H.
    Friedman, Henry
    Vredenburgh, James J.
    NEURO-ONCOLOGY, 2012, 14 : 79 - 79
  • [10] THE ADDITION OF BEVACIZUMAB TO TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Vredenburgh, James J.
    Desjardins, Annick
    Reardon, David A.
    Peters, Katherine B.
    Kirkpatrick, John P.
    Herndon, James E., II
    Coan, April D.
    Bailey, Leighann
    Janney, Dorothea
    Lu, Cynthia
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2011, 13 : 89 - 90